313350-44-6

Basic information

• Product Name: 3-Pyridinecarbonyl chloride, 6-cyano- (9CI)
• Synonyms: 3-Pyridinecarbonyl chloride, 6-cyano- (9CI);6-cyanonicotinoyl chloride;6-cyano-3-Pyridinecarbonyl chloride
• CAS NO: 313350-44-6
• Molecular Formula: C₇H₃ClN₂O
• Molecular Weight: 166.56452
• Product Categories: ACIDHALIDE
• Mol File: 313350-44-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Pyridinecarbonyl chloride, 6-cyano- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarbonyl chloride, 6-cyano- (9CI)(313350-44-6)
• EPA Substance Registry System: 3-Pyridinecarbonyl chloride, 6-cyano- (9CI)(313350-44-6)

Safety Data

• Hazardous Substances Data: 313350-44-6(Hazardous Substances Data)

Upstream product

• 2398-81-4 Nicotinic acid N-oxide 
• 70165-31-0 6-cyanonicotinic acid 

Downstream Products

• 1421502-77-3 C₂₈H₂₂FN₇O₂ 
• 1421502-78-4 C₂₉H₂₄FN₇O₂ 
• 125117-98-8 5-isocyanatopicolinonitrile 

Relevant articles and documents

Novel coordinating motifs for lanthanide(III) ions based on 5-(2-pyridyl)tetrazole and 5-(2-pyridyl-1-oxide)tetrazole. Potential new contrast agents

Water-soluble and neutral Ln(III) and Zn (II) complexes of pyridine- and (pyridine-1-oxide)tetrazole have been synthesized and the Gd derivatives have great potential as high-relaxivity low-osmolarity MRI contrast agents.

(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6- (trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist

A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)4-[4-cyano-3-(trifluoromethyl)phenyl]-2, 5-dimethyl-N-[6(triflouromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED50 = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.

NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS

This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.